Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immuron Ltd ADR
(NQ:
IMRN
)
2.690
-0.080 (-2.89%)
Streaming Delayed Price
Updated: 3:52 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immuron Ltd ADR
< Previous
1
2
3
4
5
Next >
Immuron Clinical Trials Update
December 22, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
December 04, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore Investor Webinar Presentation
November 28, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO Steven Lydeamore Investor Webinar Presentation
November 13, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron welcomes launch of Travelan on Amazon US
July 26, 2023
--News Direct--
Via
News Direct
FDA Lifts Clinical Hold From Immuron's New Campylobacter ETEC Therapeutic Study
May 08, 2023
Immuron Limited (NASDAQ: IMRN) has announced that the U.S.
Via
Benzinga
Why Immuron Stock Is Soaring Today
May 08, 2023
Immuron Ltd (NASDAQ: IMRN) shares are trading higher Monday after the company announced the FDA removed the clinical hold on its new C
Via
Benzinga
Immuron CEO Steven Lydeamore presented at AusBioInvest
October 30, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces Travelan® Clinical Study Cohort 2 commences
October 18, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron achieves record quarterly Travelan® sales
October 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron hails record monthly sales of Travelan
September 14, 2023
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®....
Via
TheNewswire.com
Immuron hails record monthly sales of Travelan
September 14, 2023
--News Direct--
Via
News Direct
Immuron achieves record monthly Travelan® sales
September 13, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
September 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron to present at the Military Health System Research Symposium
August 14, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron welcomes launch of Travelan on Amazon US
July 26, 2023
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) chief commercial officer Flavio Palumbo speaks with Proactive following the news its Travelan product has launched on Amazon US.
Via
TheNewswire.com
Immuron Announces First Patients Enrolled in Travelan® Clinical Study
July 25, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to present at Bioshares
July 24, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Business Update - Ateria Health launches Juvia™ in Australia
July 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron FY23 Sales increase 136% on FY22 Sales
July 05, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Chairman Transition
June 30, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Business Update: Letter to Shareholders
June 22, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Initiates Recruitment of Travelan® Clinical Study
May 30, 2023
From
Immuron Limited
Via
GlobeNewswire
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
May 09, 2023
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Nasdaq Edges Higher; Six Flags Reports Upbeat Results
May 08, 2023
U.S. stocks traded mixed toward the end of trading, with the S&P 500 and Nasdaq Composite turning higher later during the session on Monday. The Dow traded down 0.20% to 33,606.80 while the NASDAQ rose...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
May 08, 2023
Via
Benzinga
Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 08, 2023
Gainers Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China.
Via
Benzinga
Crude Oil Rises Over 2%; US Wholesale Inventories Unchanged For March
May 08, 2023
U.S. stocks traded slightly lower midway through trading, with the Nasdaq Composite dropping around 20 points on Monday. The Dow traded down 0.14% to 33,626.85 while the NASDAQ fell 0.18% to 12,212.88....
Via
Benzinga
Palantir (PLTR) Stock Pops Ahead of Earnings
May 08, 2023
Palantir (PLTR) stock is a hot topic on Monday as investors prepare for the company to report earnings after today's closing bell.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 08, 2023
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.